Bone marrow colony-stimulating factor and tumor resistance-enhancing activity of postendotoxin mouse sera.
The passive transfer of postendotoxin mouse serum could enhance nonspecific resistance to the development of TA3-Ha transplantable ascites tumor in mice. The postendotoxin serum was not directly cytotoxic to TA3-Ha tumor cells in vitro, nor did it contain significant amounts of residual endotoxin, but it was rich in colony-stimulating factors (CSFs). High-titer CSF serum could be induced by endotoxic lipopolysaccharide (LPS). Nonendotoxic, lipid-free, and polysaccharide-rich hydrolytic breakdown product of LPS (called PS) was less potent but still active in CSF induction. There was a correlation between the level of CSF stimulation and the capacity of the sera to transfer tumor resistance (TUR). Those LPS preparations that had the highest CSF-inducing capacity were the most potent in TUR enhancement. Suppression of CSF production by treatment with theophylline or epinephrine, enhancers of cyclic AMP/cyclic GMP ratios, lowered the enhancement of TUR by endotoxic LPS. The infection of serum donor mice with bacillus Calmette-Guérin (BCG) 18 days prior to LPS treatment gave the highest serum CSF levels and the most potent TUR-inducing serum preparation. Even more notable was the finding that the nontoxic PS preparation could replace toxic LPS in the above BCG-LPS system. The serum harvested from BCG-infected mice 2 hr after PS injection was similarly effective in the passive transfer of TUR.
D000818:Animals; D001500:BCG Vaccine; D002417:Cattle; D003115:Colony-Stimulating Factors / Q000097:blood / Q000627:therapeutic use*; D004731:Endotoxins / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006023:Glycoproteins / Q000627:therapeutic use*; D008070:Lipopolysaccharides / Q000627:therapeutic use*; D051379:Mice; D009163:Mycobacterium bovis; D009374:Neoplasms, Experimental / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use; D013806:Theophylline / Q000494:pharmacology; D014380:Tuberculosis, Bovine / Q000097:blood
D001500:BCG Vaccine; D003115:Colony-Stimulating Factors; D004731:Endotoxins; D006023:Glycoproteins; D008070:Lipopolysaccharides; D011135:Polysaccharides, Bacterial; D013806:Theophylline; D004837:Epinephrine